ES2399617T3 - Regiones de marco de inmunoglobulina que demuestran estabilidad potenciada en el entorno intracelulcar y métodos de identificación de las mismas - Google Patents

Regiones de marco de inmunoglobulina que demuestran estabilidad potenciada en el entorno intracelulcar y métodos de identificación de las mismas Download PDF

Info

Publication number
ES2399617T3
ES2399617T3 ES03732434T ES03732434T ES2399617T3 ES 2399617 T3 ES2399617 T3 ES 2399617T3 ES 03732434 T ES03732434 T ES 03732434T ES 03732434 T ES03732434 T ES 03732434T ES 2399617 T3 ES2399617 T3 ES 2399617T3
Authority
ES
Spain
Prior art keywords
enhanced stability
framework regions
identification methods
intracellular environment
immunoglobulin framework
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03732434T
Other languages
English (en)
Inventor
Kathrin Tissot
Stefan Ewert
Adrian Auf Der Maur
Alcide Barberis
Dominik Escher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esbatech a Novartis Co LLC
Original Assignee
Esbatech a Novartis Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esbatech a Novartis Co LLC filed Critical Esbatech a Novartis Co LLC
Application granted granted Critical
Publication of ES2399617T3 publication Critical patent/ES2399617T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C07K2317/82—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies functional in the cytoplasm, the inner aspect of the cell membrane, the nucleus or the mitochondria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Región de marco de cadena sencilla que tiene la estructura general: NH2-VL-enlazador-VH-COOH; o NH2-VH-enlazador-VL-COOH, en la que (i) la región de marco de VH tiene la secuencia de aminoácidos J (Seq. Id. No. 10) VQLVQSGAEVKKPGASVKVSCTASGYSFTGYFLHWVRQAPGQGLEWMGRINPDSGDT IYAQKFQDRVTL TRDTSIGTVYMEL TSL TSDDTA VYYCARVPRGTYLDPWDYFDYWG QGTL VTVSS; y (ii) la región de marco de VL tiene la secuencia de aminoácidos B (Seq. Id. No. 2) EIVL TQSPSSLSASVGDRVTL TCRASQGIRNELAWYQQRPGKAPKRLlYAGSILQSG VPSRFSGSGSGTEFTL TISSLQPEDVA VYYCQQYVSLPYMFGQGTKVDIKR; o una variante de las mismas que presenta una identidad del 90% o superior con la región de marco decadena sencilla a la vez que mantiene una estabilidad potenciada según se determina mediante el ensayodel ejemplo 2.
ES03732434T 2002-05-22 2003-05-21 Regiones de marco de inmunoglobulina que demuestran estabilidad potenciada en el entorno intracelulcar y métodos de identificación de las mismas Expired - Lifetime ES2399617T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38264902P 2002-05-22 2002-05-22
US382649P 2002-05-22
US43825603P 2003-01-03 2003-01-03
US438256P 2003-01-03
PCT/EP2003/005324 WO2003097697A2 (en) 2002-05-22 2003-05-21 Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same

Publications (1)

Publication Number Publication Date
ES2399617T3 true ES2399617T3 (es) 2013-04-02

Family

ID=29553590

Family Applications (3)

Application Number Title Priority Date Filing Date
ES10010455.3T Expired - Lifetime ES2656427T3 (es) 2002-05-22 2003-05-21 Marcos de inmunoglobulina que demuestran estabilidad mejorada en el ambiente intracelular y métodos para su identificación
ES03732434T Expired - Lifetime ES2399617T3 (es) 2002-05-22 2003-05-21 Regiones de marco de inmunoglobulina que demuestran estabilidad potenciada en el entorno intracelulcar y métodos de identificación de las mismas
ES10009857.3T Expired - Lifetime ES2537104T3 (es) 2002-05-22 2003-05-21 Regiones de marco de inmunoglobulina que demuestran estabilidad potenciada en el entorno intracelular y métodos de identificación de las mismas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES10010455.3T Expired - Lifetime ES2656427T3 (es) 2002-05-22 2003-05-21 Marcos de inmunoglobulina que demuestran estabilidad mejorada en el ambiente intracelular y métodos para su identificación

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES10009857.3T Expired - Lifetime ES2537104T3 (es) 2002-05-22 2003-05-21 Regiones de marco de inmunoglobulina que demuestran estabilidad potenciada en el entorno intracelular y métodos de identificación de las mismas

Country Status (14)

Country Link
US (5) US8853362B2 (es)
EP (5) EP3656787A1 (es)
JP (10) JP2006508638A (es)
CN (4) CN105175535A (es)
AU (2) AU2003238370B2 (es)
CA (2) CA2867542C (es)
CY (1) CY1114225T1 (es)
DK (2) DK2332989T3 (es)
ES (3) ES2656427T3 (es)
HU (1) HUE048922T2 (es)
NZ (1) NZ536412A (es)
PT (2) PT2332989E (es)
SI (2) SI2332989T1 (es)
WO (1) WO2003097697A2 (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0226727D0 (en) * 2002-11-15 2002-12-24 Medical Res Council Intrabodies
WO2006099747A1 (en) 2005-03-25 2006-09-28 National Research Council Of Canada Method for isolation of soluble polypeptides
AU2011265593B2 (en) * 2005-06-07 2013-08-15 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting TNFalpha
DK2390267T3 (da) 2005-06-07 2013-08-26 Esbatech A Novartis Co Llc Stabile og opløselige antistoffer, der hæmmer TNF(alfa)
AU2016204739C1 (en) * 2005-06-07 2017-10-19 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting TNFalpha
AU2013207650B2 (en) * 2005-06-07 2016-04-21 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting TNFalpha
EP2013236B1 (en) * 2006-04-28 2015-06-17 Delenex Therapeutics AG Antibodies binding to the extracellular domain of the receptor tyrosine kinase alk
AU2007272224B2 (en) 2006-07-10 2013-05-02 Novartis Ag scFv antibodies which pass epithelial and/or endothelial layers
CN103275216B (zh) * 2007-03-12 2015-05-06 艾斯巴技术-诺华有限责任公司 单链抗体的基于序列的工程改造和最优化
WO2008131575A2 (en) * 2007-04-27 2008-11-06 Esbatech Ag Anti-alk antibodies suitable for treating metastatic cancers or tumors
KR101530723B1 (ko) * 2007-06-25 2015-06-22 에스바테크 - 어 노바티스 컴파니 엘엘씨 단일 쇄 항체의 서열에 기초한 공학처리 및 최적화
DK2158315T3 (en) * 2007-06-25 2016-06-06 Esbatech Alcon Biomed Res Unit Methods of modifying antibodies and modified antibodies with improved functional properties
CN101842388B (zh) 2007-09-13 2013-09-04 德勒尼克斯治疗股份公司 针对β淀粉样肽的人源化抗体
HUE038432T2 (hu) 2008-06-25 2018-10-29 Esbatech Alcon Biomed Res Unit Nyúl antitestek humanizálása egy univerzális antitest keret alkalmazásával
ES2771150T3 (es) * 2008-06-25 2020-07-06 Novartis Ag Humanización de anticuerpos de conejo usando un armazón de anticuerpo universal
ES2890405T3 (es) 2008-06-25 2022-01-19 Novartis Ag Humanización de anticuerpos de conejo usando un armazón de anticuerpo universal
AU2013202997B2 (en) * 2008-06-25 2015-01-22 Novartis Ag STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFalpha
AU2016273957C1 (en) * 2008-06-25 2019-04-18 Novartis Ag STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFa
AU2015201794B2 (en) * 2008-06-25 2017-01-19 Novartis Ag STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFa
ES2687259T5 (es) * 2008-06-25 2022-10-14 Novartis Ag Anticuerpos estables y solubles que inhiben TNF
HRP20241467T1 (hr) 2008-06-25 2025-01-03 Novartis Ag Stabilna i topljiva protutijela koja inhibiraju vegf
US9556265B2 (en) 2008-06-25 2017-01-31 Esbatech, An Alcon Biomedical Research Unit Llc Solubility optimization of immunobinders
CA2729185A1 (en) 2008-06-30 2010-01-21 Esbatech, An Alcon Biomedical Research Unit Llc Methods and compositions for modifying immunobinders
EP2303230A2 (en) 2008-07-10 2011-04-06 ESBATech, an Alcon Biomedical Research Unit LLC Methods and compositions for enhanced delivery of macromolecules
RU2577965C2 (ru) * 2009-02-24 2016-03-20 ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи Способ идентификации иммунных связывающих веществ поверхностных антигенов клетки
CA2744103C (en) 2009-02-24 2018-01-02 Esbatech, An Alcon Biomedical Research Unit Llc Methods for identifying immunobinders of cell-surface antigens
US8399625B1 (en) 2009-06-25 2013-03-19 ESBATech, an Alcon Biomedical Research Unit, LLC Acceptor framework for CDR grafting
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
EP2476754A1 (en) * 2011-01-14 2012-07-18 Bundesrepublik Deutschland, Letztvertreten Durch Den Präsidenten Des Paul-Ehrlich-Instituts Methods for the identification and repair of amino acid residues destabilizing single-chain variable fragments (scFv)
DK2744931T3 (en) 2011-08-18 2018-08-06 Affinity Biosciences Pty Ltd SOLUBLE POLYPEPTIDES
AR088403A1 (es) 2011-10-20 2014-05-28 Esbatech A Novartis Co Llc Anticuerpo de union a multiples antigenos estable
WO2014030780A1 (en) * 2012-08-22 2014-02-27 Mogam Biotechnology Research Institute Screening and engineering method of super-stable immunoglobulin variable domains and their uses
US9404930B2 (en) 2012-11-05 2016-08-02 Delenex Therapeutics Ag Antibody to human IL-1 beta
EP4001307A1 (en) 2012-12-17 2022-05-25 Cell Medica Inc. Antibodies against il-1 beta
JP2016506974A (ja) * 2013-02-15 2016-03-07 エスバテック − ア ノバルティスカンパニー エルエルシー Ｃｄｒグラフトのためのアクセプターフレームワーク
HK1219485A1 (zh) 2013-02-20 2017-04-07 Esbatech - A Novartis Company Llc 用於cdr移植的受体框架
HUE052232T2 (hu) 2013-05-06 2021-04-28 Scholar Rock Inc Készítmények és eljárások növekedési faktor modulálására
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
US20170306046A1 (en) 2014-11-12 2017-10-26 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
MX2018004515A (es) * 2015-10-13 2019-04-15 Eureka Therapeutics Inc Agentes de anticuerpo especificos para cd19 humano y usos de los mismos.
CN116059316A (zh) 2015-10-23 2023-05-05 优瑞科生物技术公司 抗体/t细胞受体嵌合构建体及其用途
CN108463248B (zh) 2015-11-12 2022-10-21 西雅图基因公司 聚糖相互作用化合物及使用方法
EP4086285A1 (en) 2016-02-25 2022-11-09 Cell Medica Switzerland AG Binding members to pd-l1
AU2017331256B2 (en) 2016-09-21 2024-11-07 Aptevo Research And Development Llc CD123 binding proteins and related compositions and methods
EP3541847A4 (en) 2016-11-17 2020-07-08 Seattle Genetics, Inc. COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
EP3589319A4 (en) 2017-03-03 2021-07-14 Seagen Inc. GLYCAN INTERACTING COMPOUNDS AND METHOD OF USE
CN112218621A (zh) * 2018-04-10 2021-01-12 西北大学 包含基于靶向亲和域的膜蛋白的胞外囊泡
WO2020069349A1 (en) * 2018-09-27 2020-04-02 Colorado State University Research Foundation Scfv's for live cell imaging and other uses
US12285437B2 (en) 2019-10-30 2025-04-29 The Research Foundation For The State University Of New York Reversing the undesirable pH-profile of doxorubicin via activation of a disubstituted maleamic acid prodrug at tumor acidity
US11524998B2 (en) 2020-07-16 2022-12-13 Novartis Ag Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
CA3172265A1 (en) 2021-03-10 2022-09-15 Dimitri BIELI Antibodies against tdp-43 and methods of using the same
WO2023139292A1 (en) 2022-01-24 2023-07-27 Cambridge Enterprise Limited Tau therapy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
US5817311A (en) * 1993-03-05 1998-10-06 Universite Catholique De Louvain Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies
DE4425115A1 (de) 1994-07-15 1996-01-18 Boehringer Mannheim Gmbh Verfahren zur Modifizierung der Stabilität von Antikörpern
US6696248B1 (en) * 1995-08-18 2004-02-24 Morphosys Ag Protein/(poly)peptide libraries
ATE219517T1 (de) 1995-08-18 2002-07-15 Morphosys Ag Protein-/(poly)peptidbibliotheken
US6262238B1 (en) 1997-01-14 2001-07-17 Roche Diagnostic, Gmbh Process for modifying the stability of antibodies
AU3587599A (en) 1997-11-28 1999-06-16 Invitrogen Corporation Single chain monoclonal antibody fusion reagents that regulate transcript ion in vivo
GB2344886B (en) 1999-03-10 2000-11-01 Medical Res Council Selection of intracellular immunoglobulins
ATE273323T1 (de) 1999-12-28 2004-08-15 Esbatech Ag INTRAKÖRPER MIT DEFINIERTER STRUKTUR (ßFRAMEWORKß), DIE IN EINER REDUZIERENDEN UMGEBUNG STABIL IST, UND IHRE VERWENDUNGEN
GB0008419D0 (en) 2000-04-05 2000-05-24 Bioinvent Int Ab A method for invitro molecular evolution of antibody function
EP1156062A1 (en) 2000-05-12 2001-11-21 GPC Biotech AG Immunomodulatory human MHC class II antigen-binding peptides/proteins
US6410271B1 (en) 2000-06-23 2002-06-25 Genetastix Corporation Generation of highly diverse library of expression vectors via homologous recombination in yeast
DE10039191C1 (de) 2000-08-10 2002-01-17 Infineon Technologies Ag Hochfrequenz-Eingangsstufe

Also Published As

Publication number Publication date
HK1217712A1 (en) 2017-01-20
EP1506236B1 (en) 2013-01-23
JP2020171286A (ja) 2020-10-22
JP2010187678A (ja) 2010-09-02
US20170107272A1 (en) 2017-04-20
SI2947095T1 (sl) 2020-04-30
US9518108B2 (en) 2016-12-13
DK1506236T3 (da) 2013-03-04
AU2010202634B2 (en) 2012-08-23
EP3656787A1 (en) 2020-05-27
JP2015214583A (ja) 2015-12-03
CN1662556A (zh) 2005-08-31
CN103739706B (zh) 2015-11-18
ES2537104T3 (es) 2015-06-02
NZ536412A (en) 2008-10-31
PT2332989E (pt) 2015-08-05
EP1506236A2 (en) 2005-02-16
AU2003238370A1 (en) 2003-12-02
CA2483285C (en) 2015-01-27
HK1071378A1 (en) 2005-07-15
EP2314622B1 (en) 2017-10-18
JP2013256533A (ja) 2013-12-26
US10570190B2 (en) 2020-02-25
US20150057191A1 (en) 2015-02-26
EP2314622A1 (en) 2011-04-27
CA2483285A1 (en) 2003-11-27
JP2012228272A (ja) 2012-11-22
JP6261136B2 (ja) 2018-01-17
CA2867542C (en) 2020-04-14
CY1114225T1 (el) 2016-08-31
WO2003097697A2 (en) 2003-11-27
EP2332989B1 (en) 2015-04-01
US20190119361A1 (en) 2019-04-25
US20200165322A1 (en) 2020-05-28
EP2332989A1 (en) 2011-06-15
CN102093477B (zh) 2014-02-26
JP2006508638A (ja) 2006-03-16
CN102093477A (zh) 2011-06-15
EP2947095B1 (en) 2019-10-02
WO2003097697A3 (en) 2004-12-09
AU2003238370B2 (en) 2010-04-29
CN1662556B (zh) 2013-05-01
JP2015227372A (ja) 2015-12-17
US10125186B2 (en) 2018-11-13
JP6918033B2 (ja) 2021-08-11
AU2010202634A1 (en) 2010-07-15
US8853362B2 (en) 2014-10-07
JP2019058191A (ja) 2019-04-18
CN103739706A (zh) 2014-04-23
CN105175535A (zh) 2015-12-23
EP2947095A1 (en) 2015-11-25
DK2332989T3 (en) 2015-05-11
JP2017201990A (ja) 2017-11-16
CA2867542A1 (en) 2003-11-27
ES2656427T3 (es) 2018-02-27
PT1506236E (pt) 2013-03-27
JP6075836B2 (ja) 2017-02-08
SI2332989T1 (sl) 2015-06-30
HUE048922T2 (hu) 2020-09-28
JP6100544B2 (ja) 2017-03-22
US20060035320A1 (en) 2006-02-16
JP2013078343A (ja) 2013-05-02
HK1152320A1 (en) 2012-02-24

Similar Documents

Publication Publication Date Title
ES2656427T3 (es) Marcos de inmunoglobulina que demuestran estabilidad mejorada en el ambiente intracelular y métodos para su identificación
TH188977S (th) แก้ว
TH188978S (th) แก้ว
TH188975S (th) แก้ว
TH188979S (th) แก้ว
TH188980S (th) แก้ว
TH187209S (th) โคมไฟ
TH188474S (th) โคมไฟตั้งโต๊ะ
TH186360S (th) โคมไฟตั้งโต๊ะ
TH190591S (th) แก้ว
TH188035S (th) แท่นรองรับ
TH187210S (th) โคมไฟ
TH187724S (th) โคมไฟ
TH187723S (th) โคมไฟ
TH187213S (th) โคมไฟ
TH187010S (th) อิฐบล็อก
TH188187S (th) เครื่องฟอกอากาศ
TH191426S (th) แก้ว
TH187036S (th) เครื่องฟอกอากาศ
TH187671S (th) เครื่องดนตรีประเภทเป่า
TH187707S (th) เก้าอี้
TH187705S (th) เก้าอี้
TH186135S (th) หน้าปัดนาฬิกา
TH187813S (th) ชิ้นส่วนผนังสำเร็จรูป
TH187014S (th) เก้าอี้